| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $2,857,000 | 2 | 20 |
Sells | $145,094 | 8 | 80 |
| Redmile Group, LLC | 10 percent owner | 2 | $2.86M | 1 | $52,479 | $2.8M |
| Hug Peter | director | 0 | $0 | 1 | $3,448 | $-3,448 |
| Monges Viviane | director | 0 | $0 | 1 | $4,153 | $-4,153 |
| Pfisterer Thomas | director | 0 | $0 | 1 | $4,153 | $-4,153 |
| Azelby Robert | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| BIZZARI JEAN-PIERRE | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| Sandor Victor | director | 0 | $0 | 1 | $20,216 | $-20,216 |
| Squarer Ron | director | 0 | $0 | 1 | $20,216 | $-20,216 |
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Over the last 12 months, insiders at ADC Therapeutics SA have bought $2.86M and sold $145,094 worth of ADC Therapeutics SA stock.
On average, over the past 5 years, insiders at ADC Therapeutics SA have bought $2.86M and sold $139,145 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Redmile Group, LLC (10 percent owner) — $2.86M.
The last purchase of 200,000 shares for transaction amount of $609,000 was made by Redmile Group, LLC (10 percent owner) on 2024‑12‑11.
| 2024-12-11 | Redmile Group, LLC | 10 percent owner | 200,000 0.2806% | $3.04 | $609,000 | -24.77% | ||
| 2024-12-04 | Sale | Redmile Group, LLC | 10 percent owner | 25,352 0.0263% | $2.07 | $52,479 | -18.84% | |
| 2024-07-01 | Redmile Group, LLC | 10 percent owner | 800,000 0.9607% | $2.81 | $2.25M | -43.75% | ||
| 2024-06-17 | Sale | Pfisterer Thomas | director | 1,437 0.0018% | $2.89 | $4,153 | -24.11% | |
| 2024-06-17 | Sale | Hug Peter | director | 1,193 0.0015% | $2.89 | $3,448 | -24.11% | |
| 2024-06-17 | Sale | Monges Viviane | director | 1,437 0.0018% | $2.89 | $4,153 | -24.11% | |
| 2024-06-17 | Sale | Sandor Victor | director | 6,995 0.0086% | $2.89 | $20,216 | -24.11% | |
| 2024-06-17 | Sale | Squarer Ron | director | 6,995 0.0086% | $2.89 | $20,216 | -24.11% | |
| 2024-06-17 | Sale | BIZZARI JEAN-PIERRE | director | 6,995 0.0086% | $2.89 | $20,216 | -24.11% | |
| 2024-06-17 | Sale | Azelby Robert | director | 6,995 0.0086% | $2.89 | $20,216 | -24.11% | |
| 2024-05-07 | Sale | MALLIK AMEET | Chief Executive Officer | 29,731 0.0569% | $4.48 | $133,195 | -43.37% | |
| 2009-03-06 | FORET MICKEY P | director | 10,000 0.0118% | $2.75 | $27,500 | |||
| 2007-06-20 | Sale | SWITZ ROBERT E | PRES & CEO | 8,000 0.065% | $19.02 | $152,160 | ||
| 2006-06-20 | Rehfeld John E | director | 1,000 0.0069% | $16.14 | $16,135 | |||
| 2006-06-07 | FORET MICKEY P | director | 10,000 0.0746% | $17.46 | $174,600 | |||
| 2006-06-07 | MARTIN LOIS M | director | 1,000 0.0075% | $17.46 | $17,460 | |||
| 2006-06-05 | BLANCHARD JOHN A III | director | 15,000 0.1136% | $17.72 | $265,856 | |||
| 2004-01-16 | Sale | JOHNSON B KRISTINE | director | 16,000 0.0251% | $3.67 | $58,720 |
| Increased Positions | 40 | +45.45% | 2M | +3.21% |
| Decreased Positions | 33 | -37.5% | 3M | -5.84% |
| New Positions | 14 | New | 329,380 | New |
| Sold Out Positions | 13 | Sold Out | 420,035 | Sold Out |
| Total Postitions | 95 | +7.95% | 55M | -2.64% |
| Redmile Group, Llc | $22,560.00 | 15.83% | 15.67M | -2,486 | -0.02% | 2024-12-31 |
| Prosight Management, Lp | $13,702.00 | 9.61% | 9.52M | -121,237 | -1.26% | 2024-12-31 |
| Orbimed Advisors Llc | $8,595.00 | 6.03% | 5.97M | +1M | +31.64% | 2024-12-31 |
| Blackrock, Inc. | $7,076.00 | 4.96% | 4.91M | -98,229 | -1.96% | 2025-03-31 |
| Morgan Stanley | $5,697.00 | 4% | 3.96M | +915,378 | +30.1% | 2024-12-31 |
| Woodline Partners Lp | $2,785.00 | 1.95% | 1.93M | +2M | New | 2024-12-31 |
| Goldman Sachs Group Inc | $2,409.00 | 1.69% | 1.67M | -15,417 | -0.91% | 2024-12-31 |
| Platinum Investment Management Ltd | $2,322.00 | 1.63% | 1.61M | +168,040 | +11.63% | 2024-12-31 |
| Bank Of America Corp /De/ | $1,859.00 | 1.3% | 1.29M | -1M | -48.31% | 2024-12-31 |
| State Street Corp | $1,711.00 | 1.2% | 1.19M | +82,183 | +7.43% | 2024-12-31 |